## TABLE 1. The impact assessment SARS-CoV-2 virus on cancer patinets

1. Clinical trials are characterized by a number of procedures that require the patient to be in constant contact with the research team. Would you agree to participate in a clinical trial in the face of a coronavirus pandemic if you had to be in hospital more often than with standard treatment?

Yes	9	26%	z-test	-4,0638	< 0,00001
No	26	74%			

2. Oncology is the field in which the most clinical trials are conducted in Poland, the percentage of Polish patients participating in research on medicinal products is constantly growing. In your opinion, can the current situation stop the development of clinical trials in Poland?

Yes	9	26%	$\chi^2$	16,653	0,0002
No	3	9%			
I don't know	23	65%			

3. Do you think that the necessary precautions in hospitals to minimize the risk of spreading coronavirus are sufficient to allow clinical trials and safe admission to patients?

Yes	7	20%	$\chi^2$	3,508	0,17312
No	12	34%			
I don't know	16	45%			

4. The informed consent form describes the risk of adverse events associated with the clinical trial. The form does not contain information about the effect of coronavirus infection during treatment and its effects. In the absence of such information, would you decide to participate in a clinical trial?

			,		
Yes	4	11%	z-test	-6,4542	< 0,00001
No	31	89%			

5. Patients undergoing oncological treatment often have reduced immunity, which may increase the risk of coronavirus infection. Would you decide to participate in a clinical trial knowing that you may be at a greater risk of coronavirus infection during your treatment in a clinical trial?

O					
Yes	8	29%	z-test	-4,5419	< 0,00001
No	27	71%			

6. Do you think about resigning from participation in a clinical trial due to the spread of coronavirus in Poland? If the patient has already completed the study, would he have thought about ending the study?

Yes	7	20%	z-test	-5,02	< 0,00001
No	28	80%			

7. Is your fear of cancer progression greater than your fear of coronavirus infection?

I am more afraid of					
cancer progression	29	83%	z-test	5,4981	< 0,00001
I'm more afraid of					
coronavirus	6	17%			

8. What do you think the research team should do in a clinical trial to minimize the risk of coronavirus infection? (several answers can be given)

a) Limit contact with		
the study participant		
to the necessary		
minimum	35	100%
b) Inspection visits		
by telephone	26	74%
c) Abandon		
additional		
procedures, e.g.		
additional blood		
donations	30	85%
d) Extend treatment		
cycles	6	17%
e) Take no action	0	

9. What do you think the sponsor of the clinical trial (pharmaceutical company) should do to protect the research team and clinical trial participants in the face of a coronavirus pandemic? (several answers can be given)

a) Suspend the		
clinical trial	6	17%
b) Submit		
information to the		
research team about		
the possible effect		
of coronavirus on		
study drug treatment	35	35%
c) Provide protective		
measures for the		
research team and		
participants	29	82%
d) Take no action	0	

10. Would you feel safer if the research team contacted you during the coronavirus pandemic and asked about your health?

Yes	35	100%	z-test	8,3666	< 0,00001
No	0	0%			

11. What do you think a patient taking part in a clinical trial should do if he notices the following symptoms, i.e. fever, shortness of breath, coughing? (you can choose several answers)

Notify the sanitary-		
epidemiological		
station	29	82%
Call an ambulance	15	43%
see an oncologist	5	14%

No action	0	0%
ino action	U	0 70

z-test to qust. 2		Yes	No	I don't know		Yes	No
	Yes	X	1,9028	-3,359	Yes	X	0,05744
	No	х	х	-4,9473	No	X	Х

I don't know
0,0008

<0,00001

z-test to qust. 3		Yes	No	I don't know	7	Yes	No
	Yes	X	-1,3439	-2,2902	Yes	X	0,18024
	No	X	X	-0,9759	No	X	X
	I don't know	X	X	X	I don't know	X	X

I don't know 0,02202 0,32708 x

z-test to ques. 8		a) Limit con	b) Inspection	c) Abandon	d) Extend tr	e) Take no a	ction
	a) Limit con	X	3,2137	2,3205	7,0365	8,3666	
	b) Inspectio	X	X	-1,1952	4,7986	6,4315	
	c) Abandon	X	X	X	5,7394	7,2457	
	d) Extend tr	X	X	X	X	2,5617	
	e) Take no a	X	X	X	X	X	

z-test to quest. 9		a) Suspend	b) Submit in	c) Provide p	d) Take no a	action
	a) Suspend	X	-7,0365	-5,4981	2,5617	
	b) Submit in	X	X	2,5617	8,3666	
	c) Provide p	X	X	X	7,0365	
	d) Take no a	X	X	X	X	

z-test to quest. 11		Notify the sa	Call an amb	see an oncol	No action
	Notify the s	X	3,4631	5,7394	7,0365
	Call an amb	X	X	2,6458	4,3693
	see an onco	X	X	X	2,3205
	No action	X	X	X	X